A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Last updated: April 2, 2025
Sponsor: Celgene
Overall Status: Active - Not Recruiting

Phase

1

Condition

Multiple Myeloma

Lymphoproliferative Disorders

Leukemia

Treatment

Dexamethasone

Alnuctamab

Mezigdomide

Clinical Study ID

NCT06163898
CA058-002
2023-504367-16-00
U1111-1283-8970
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Participant has a history of RRMM, and must:

  • Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.

  • Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.

Exclusion

Exclusion Criteria:

• Must not have previously received alnuctamab or mezigdomide.

Note: Other protocol-defined inclusion/exclusion criteria apply

Study Design

Total Participants: 156
Treatment Group(s): 3
Primary Treatment: Dexamethasone
Phase: 1
Study Start date:
February 27, 2024
Estimated Completion Date:
May 30, 2025

Connect with a study center

  • Local Institution - 0004

    Aarhus, Midtjylland 8200
    Denmark

    Site Not Available

  • Local Institution - 0007

    Odense, Syddanmark 5000
    Denmark

    Site Not Available

  • Local Institution - 0008

    Lille, Nord 59000
    France

    Site Not Available

  • Local Institution - 0009

    Nantes, Pays-de-la-Loire 44000
    France

    Site Not Available

  • Local Institution - 0027

    Paris, 75010
    France

    Site Not Available

  • Local Institution - 0037

    Essen, Nordrhein-Westfalen 45122
    Germany

    Site Not Available

  • Local Institution - 0036

    Heidelberg, D-69120
    Germany

    Site Not Available

  • Local Institution - 0038

    Wuerzburg, 97080
    Germany

    Site Not Available

  • Local Institution - 0021

    Petah-Tikva, HaMerkaz 4910021
    Israel

    Site Not Available

  • Rabin Medical Center

    Petah-Tikva, HaMerkaz 4910021
    Israel

    Active - Recruiting

  • Local Institution - 0030

    Ramat Gan, HaMerkaz 5262100
    Israel

    Site Not Available

  • Sheba Medical Center

    Ramat Gan, HaMerkaz 5262100
    Israel

    Active - Recruiting

  • Hadassah Medical Center

    Jerusalem, 9112001
    Israel

    Active - Recruiting

  • Local Institution - 0020

    Jerusalem, 9112001
    Israel

    Site Not Available

  • Local Institution - 0044

    Rotterdam, Zuid-Holland 3015 CE
    Netherlands

    Site Not Available

  • Local Institution - 0029

    Groningen, 9713 GZ
    Netherlands

    Site Not Available

  • Local Institution - 0039

    Málaga, Andalucía 29010
    Spain

    Site Not Available

  • Local Institution - 0023

    Santander, Cantabria 39008
    Spain

    Site Not Available

  • Local Institution - 0025

    Pamplona, Navarra 31008
    Spain

    Site Not Available

  • Local Institution - 0028

    Salamanca, 37007
    Spain

    Site Not Available

  • Local Institution - 0033

    Birmingham, Alabama 35294
    United States

    Site Not Available

  • University of Alabama at Birmingham

    Birmingham, Alabama 35294
    United States

    Active - Recruiting

  • Local Institution - 0032

    San Francisco, California 94143
    United States

    Site Not Available

  • Local Institution - 0035

    New Haven, Connecticut 06511
    United States

    Site Not Available

  • Yale New Haven Hospital-Smilow Cancer Center

    New Haven, Connecticut 06511
    United States

    Active - Recruiting

  • Local Institution - 0018

    New York, New York 10065
    United States

    Site Not Available

  • Weill Cornell Medical College

    New York, New York 10065
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.